Biosimilars in rheumatology: current perspectives and lessons learnt

SAT0142 Immunogenicity Assessment of PF-06438179, A Potential Biosimilar to Infliximab, In Healthy Volunteers

(2015) C. Udata et al.   ANNALS OF THE RHEUMATIC DISEASES

FRI0116 Pharmacokinetic Results from a Phase 1, Single-Centre, Double-Blind, Randomised, Single-Dose, Parallel Group Study Comparing 5 MG/KG IV Infusion of BOW015 and Reference Infliximab in Healthy Male Volunteers

(2015) J. Lambert et al.   ANNALS OF THE RHEUMATIC DISEASES

Recommendations on how to ensure the safety and effectiveness of biosimilars in Latin America: a point of view

(2015) Carlos Pineda et al.   CLINICAL RHEUMATOLOGY

Comparative Effectiveness of Immunosuppressants and Biologics for Inducing and Maintaining Remission in Crohn's Disease: A Network Meta-analysis

(2015) Glen S. Hazlewood et al.   GASTROENTEROLOGY

The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper

(2014) Gionata Fiorino et al.   AUTOIMMUNITY REVIEWS

The biosimilar road in inflammatory bowel disease: The right way?

(2014) Gionata Fiorino et al.   BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY

Evolution der Biologika in der Entzündungsmedizin – Biosimilars in Gastroenterologie, Rheumatologie und Dermatologie

(2014) S. Schreiber et al.   DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT

Biopharmaceuticals for rheumatic diseases in Latin America, Europe, Russia, and India: Innovators, biosimilars, and intended copies

(2014) Gilberto Castañeda-Hernández et al.   JOINT BONE SPINE

Future directions in inflammatory bowel disease management

(2014) Geert R. D'Haens et al.   Journal of Crohns & Colitis

Viewpoint: Knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization

(2014) Silvio Danese et al.   Journal of Crohns & Colitis

Etanercept biosimilars

(2014) Valderilio F. Azevedo et al.   RHEUMATOLOGY INTERNATIONAL

Biosimilars in rheumatology: the wind of change

(2013) Christian K Schneider   ANNALS OF THE RHEUMATIC DISEASES

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

(2013) Dae Hyun Yoo et al.   ANNALS OF THE RHEUMATIC DISEASES

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

(2013) Won Park et al.   ANNALS OF THE RHEUMATIC DISEASES

Meta-analysis/Systematic review Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis

(2013) Paweł Kawalec et al.   Archives of Medical Science

Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases

(2013) C. C. Mok et al.   CLINICAL RHEUMATOLOGY

Rituximab biosimilars

(2013) Edward M Vital et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Biosimilars in IBD: hope or expectation?: Table 1

(2013) Krisztina B Gecse et al.   GUT

ECCO position statement: The use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD)

(2013) Silvio Danese et al.   Journal of Crohns & Colitis

The INN crowd

(2013)   NATURE BIOTECHNOLOGY

Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis

(2013) Pauline A. van Schouwenburg et al.   Nature Reviews Rheumatology

Joint position statement by "Sociedad Española de Patología Digestiva" (Spanish Society of Gastroenterology) and "Sociedad Española de Farmacología" (Spanish Society of Pharmacology) on biosimilar therapy for inflammatory bowel disease

(2013) Federico Argüelles-Arias et al.   REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS

Biosimilars

(2013) M. Aringer et al.   ZEITSCHRIFT FUR RHEUMATOLOGIE

Who Makes It to the Base? Selection Procedure for a Physical Activity Trial Targeting People With Rheumatoid Arthritis

(2013) Birgitta Nordgren et al.   ARTHRITIS CARE & RESEARCH

The role of biosimilars in the treatment of rheumatic diseases

(2012) Thomas Dörner et al.   ANNALS OF THE RHEUMATIC DISEASES

Comparative Pharmacokinetics of HD203, a Biosimilar of Etanercept, with Marketed Etanercept (Enbrel®)

(2012) SoJeong Yi et al.   BIODRUGS

The advent of biosimilar therapies in rheumatology—“O Brave New World”

(2012) Morton A. Scheinberg et al.   Nature Reviews Rheumatology

A Comparison of Patient Characteristics and Outcomes in Selected European and U.S. Rheumatoid Arthritis Registries

(2010) Jeffrey R. Curtis et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM